18th Mar 2015 09:13
LONDON (Alliance News) - Futura Medical PLC on Wednesday said subject screening has started for a clinical study of its portfolio of three topical pain relief products.
Futura said the active ingredients in the three products, which all use the company's DermaSys transdermal delivery system, comprise diclofenac, ibuprofen and methyl salicylate.
The products will be tested in a controlled induced pain model, in which the skin of healthy volunteers will be carefully exposed to a controlled amount of ultra-violet light in order to increase the sensitivity of the skin to pain stimuli.
"We are delighted that this potentially pivotal clinical study of the three products in our topical pain relief portfolio is now under way. We look forward to receiving the read-out from the study by around the end of July this year," said Futura Chief Executive James Barder.
Shares in Futura were up 0.7% to 37.50 pence on Wednesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Futura Medical